Cibc World Markets Corp Has $6.24 Million Stake in Cencora, Inc. (NYSE:COR)

Cibc World Markets Corp increased its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 15.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 27,753 shares of the company's stock after acquiring an additional 3,764 shares during the period. Cibc World Markets Corp's holdings in Cencora were worth $6,236,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hickory Asset Management Inc. acquired a new position in Cencora during the 4th quarter worth approximately $572,000. Sylvest Advisors LLC acquired a new position in shares of Cencora in the 4th quarter valued at approximately $1,105,000. Insight Wealth Strategies LLC raised its position in shares of Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after purchasing an additional 11,232 shares in the last quarter. Cerity Partners LLC raised its position in shares of Cencora by 10.1% in the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock valued at $8,881,000 after purchasing an additional 3,610 shares in the last quarter. Finally, Vontobel Holding Ltd. raised its position in shares of Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after purchasing an additional 1,995 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of Cencora stock traded down $0.93 during trading on Friday, hitting $266.91. The stock had a trading volume of 6,526,576 shares, compared to its average volume of 1,376,560. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market cap of $51.76 billion, a P/E ratio of 37.97, a PEG ratio of 1.31 and a beta of 0.51. The business has a fifty day moving average of $250.62 and a two-hundred day moving average of $240.06. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $271.08.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.82%. Cencora's dividend payout ratio (DPR) is 31.29%.

Insider Activity

In other news, CEO Robert P. Mauch sold 4,970 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares of the company's stock, valued at $13,022,850. This represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,970 shares of company stock worth $2,998,670 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on COR. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Mizuho assumed coverage on Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target for the company. Evercore ISI boosted their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Finally, Wells Fargo & Company upped their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.